Photoionization

Cambrian Biopharma CEO James Peyer Named 2022 "BioTech Company CEO of the Year" By BioTech Breakthrough

Retrieved on: 
Friday, November 4, 2022

NEW YORK , Nov. 4, 2022 /PRNewswire/ -- Cambrian BioPharma, a multi-asset longevity biotech, today announced that its CEO, James Peyer, has been selected as "BioTech Company CEO of the Year" in the second annual BioTech Breakthrough Awards, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe.

Key Points: 
  • James Peyer, Ph.D., is CEO and Founder of Cambrian Biopharma, which is bridging the gap between academic discovery and drug development, under their Distributed Development Company (or DisCo) model.
  • Since 2019, Peyer's Cambrian has grown from three drugs more than a dozen therapeutics that are currently in development.
  • "Thank you so much to BioTech Breakthrough for honoring me and the work of my entire team in this way.
  • Congratulations to James Peyer on winning 'BioTech Company CEO of the Year' for 2022."

Cambrian BioPharma Appoints Ruth Thieroff-Ekerdt as Executive Vice President of Clinical Development

Retrieved on: 
Wednesday, September 21, 2022

NEW YORK, Sept. 21, 2022 /PRNewswire/ -- Cambrian BioPharma , a multi-asset longevity biotech, today announces the appointment of Ruth Thieroff-Ekerdt, M.D., as Executive Vice President of Clinical Development.

Key Points: 
  • NEW YORK, Sept. 21, 2022 /PRNewswire/ -- Cambrian BioPharma , a multi-asset longevity biotech, today announces the appointment of Ruth Thieroff-Ekerdt, M.D., as Executive Vice President of Clinical Development.
  • "Adding Ruth to the Cambrian team is an important step towards ensuring our work to increase healthspan while creating life-changing medicines for patients suffering from diseases today," said James Peyer, CEO, Cambrian BioPharma.
  • "Her background and vast knowledge of clinical development will allow Cambrian to thoughtfully advance our wide array of programs into human trials."
  • In her role, Dr. Thieroff-Ekerdt will be responsible for a broad range of development activities including the continuation and creation of clinical development and strategy.

Oviva Therapeutics, a Cambrian BioPharma *PipeCo, announces Seed Financing and Exclusive License with Massachusetts General Hospital to Develop Therapeutics to Extend Healthspan in Women

Retrieved on: 
Thursday, May 19, 2022

She joined Cambrian BioPharma as a Scientist in Residence in 2020 to build the foundation for Oviva.

Key Points: 
  • She joined Cambrian BioPharma as a Scientist in Residence in 2020 to build the foundation for Oviva.
  • Her intervention focuses on extending ovarian function, prompted by the fact that ovaries are the first organ to decline with age.
  • We're uncovering novel insights into ovarian physiology to develop first-in-class therapeutics that improve ovarian function and prevent aging of the ovary.
  • Donahoe and Pepin and include analogs of AMH, which Oviva aims to develop for therapeutic use in women.